Back
Atara Biotherapeutics Quote, Financials, Valuation and Earnings
Sponsored
ATRA
Sponsored
Invest. Do Good. Get Rewarded. Just $0.25/Share!
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
43
ATRA
Atara Biotherapeutics
Last Price:
10.60
Seasonality Move:
16.06%
7 Day Trial
ALL ACCESS PASS
$
7
Access The Stock Grader Trading Tool From "The King Of Quants"
More details here...Atara Biotherapeutics Price Quote
$10.60
-0.08 (-0.75%)
(Updated: November 21, 2024 at 5:55 PM ET)
Atara Biotherapeutics Key Stats
Sell
43
Atara Biotherapeutics (ATRA)
is a Sell
Day range:
$10.32 - $11.15
52-week range:
$6.50 - $39.50
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.66
P/B ratio:
0%
Volume:
108.4K
Avg. volume:
125.2K
1-year change:
-23.44%
Market cap:
$65.3M
Revenue:
$8.6M
EPS:
$-25.76
How Much Does Atara Biotherapeutics Make?
-
How Much Are Atara Biotherapeutics's Sales Annually?
ATRA Revenues are $8.6M -
How Much Profit Does Atara Biotherapeutics's Make A Year?
ATRA net income is -$276.1M
Is Atara Biotherapeutics Growing As A Company?
-
What Is Atara Biotherapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 17.8% -
What Is Atara Biotherapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Atara Biotherapeutics Stock Price Performance
-
Did Atara Biotherapeutics Stock Go Up Last Month?
Atara Biotherapeutics share price went up by 13.5% last month -
Did ATRA's Share Price Rise Over The Last Year?
ATRA share price fell by -23.44% over the past 1 year
What Is Atara Biotherapeutics 52-Week High & Low?
-
What Is Atara Biotherapeutics’s 52-Week High Share Price?
Atara Biotherapeutics has traded as high as $39.50 over the past 52 weeks -
What Is Atara Biotherapeutics’s 52-Week Low Share Price?
Atara Biotherapeutics has traded as low as $6.50 over the past 52 weeks
Atara Biotherapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Atara Biotherapeutics?
-
How Much Debt Does Atara Biotherapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Atara Biotherapeutics Have?
Cash and short term investments quarterly total is $67.2M -
What Is Atara Biotherapeutics’s Book Value Per Share?
Book value per share is -15.77
Is Atara Biotherapeutics Cash Flow Positive?
-
What Is ATRA Cash Flow From Operations?
Cash flow from operations (TTM) is -$94.7M -
What Is Atara Biotherapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $61.1M -
What Is Atara Biotherapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $15.2M
Atara Biotherapeutics Return On Invested Capital
Data Unavailable
Atara Biotherapeutics Earnings Date & Stock Price
-
What Is Atara Biotherapeutics's Stock Price Today?
A single share of ATRA can be purchased today for 10.68 -
What Is Atara Biotherapeutics’s Stock Symbol?
Atara Biotherapeutics trades on the nasdaq under the ticker symbol: ATRA -
When Is Atara Biotherapeutics’s Next Earnings Date?
The next quarterly earnings date for Atara Biotherapeutics is scheduled on March 28, 2025 -
When Is ATRA's next ex-dividend date?
Atara Biotherapeutics's next ex-dividend date is November 22, 2024 -
How To Buy Atara Biotherapeutics Stock?
You can buy Atara Biotherapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Atara Biotherapeutics Competitors
-
Who Are Atara Biotherapeutics's Competitors?
Below is a list of companies who compete with Atara Biotherapeutics or are related in some way:
Atara Biotherapeutics Dividend Yield
-
What Is ATRA Dividend Yield?
Atara Biotherapeutics’s dividend yield currently is 0% -
What Is Atara Biotherapeutics’s Payout Ratio?
Atara Biotherapeutics’s payout ratio is 0% -
When Did Atara Biotherapeutics Last Pay A Dividend?
The latest dividend pay date is November 22, 2024 -
What Is Atara Biotherapeutics’s Dividend Per Share?
Atara Biotherapeutics pays a dividend of $0.00 per share
Atara Biotherapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 85.77% |
Revenue: | 1779.79% | 14.28% |
Analyst Recommendations
Buy Recommendations: | 3 |
---|---|
Hold Recommendations: | 3 |
Sell Recommendations: | 0 |
Price Target: | 14.75 |
Upside from Last Price: | 38.11% |